Scientists say they’ve zeroed in on a cause of Alzheimer’s
By
Alicia Lasek
Dec 03, 2021
Researchers from the University of California, Riverside say they have uncovered a reason why some people with plaques and tangles in their brains do not develop Alzheimer’s disease.
Ethical considerations explored for aducanumab in Alzheimer disease
Nov 19, 2021
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
Mirtazapine does not reduce agitation in dementia patients
Nov 03, 2021
In randomized, double-blind trial, no difference seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo
Avoid antipsychotic use to lessen stroke risk in Alzheimer’s patients: study
By
Alicia Lasek
Oct 29, 2021
The increased odds of experiencing a stroke within 60 days of starting treatment suggests that even short-term antipsychotic use should be avoided if possible, investigators contend.
Elders get a cognitive boost after positive social interactions, mobile study finds
By
Alicia Lasek
Sep 15, 2021
In a smartphone-enabled study, adults aged 70 years and older had better cognitive performance the same day that they reported having more frequent, pleasant social interactions than usual — and on the...
U.S. lawmakers ramp up scrutiny of FDA following agency’s approval of controversial Alzheimer’s drug
By
Alicia Lasek
Sep 07, 2021
The FDA is being asked to help explain how Aduhelm (aducanumab) met accelerated approval criteria when so many experts — including internal advisers — have flagged insufficient safety and efficacy...
NIH highlights decade of Alzheimer’s advancements tied to small business investments
By
Alicia Lasek
Aug 11, 2021
A new paper showcases the results of 11 years of federal investment in dementia research, including advancements in care intervention, diagnostics and therapeutics.
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
First appropriate use guidance published for Alzheimer’s drug Aduhelm
By
Alicia Lasek
Jul 28, 2021
The new guidelines cover how to choose appropriate patients, safely scale up to a full dose, monitor side effects and assess effectiveness. The authors also address when to stop therapy and what patients...
To save itself, might Medicare deny coverage of controversial new Alzheimer’s drug?
By
Kimberly Marselas
Jun 28, 2021
The true price to administer aducanumab — a controversial new Alzheimer’s treatment — may actually be closer to $100,000 annually than other, lower estimates and is just one reason the Centers for...